Hirayama, K.; Yamamoto, M.; Honda, S.; Kyo, A.; Misawa, N.; Kohno, T.
Switching to Intravitreal Brolucizumab after Ranibizumab or Aflibercept Using Treat and Extend Regimen for Neovascular Age-Related Macular Degeneration in Japanese Patients: 1-Year Results and Factors Associated with Treatment Responsiveness. J. Clin. Med. 2024, 13, 4375.
https://doi.org/10.3390/jcm13154375
AMA Style
Hirayama K, Yamamoto M, Honda S, Kyo A, Misawa N, Kohno T.
Switching to Intravitreal Brolucizumab after Ranibizumab or Aflibercept Using Treat and Extend Regimen for Neovascular Age-Related Macular Degeneration in Japanese Patients: 1-Year Results and Factors Associated with Treatment Responsiveness. Journal of Clinical Medicine. 2024; 13(15):4375.
https://doi.org/10.3390/jcm13154375
Chicago/Turabian Style
Hirayama, Kumiko, Manabu Yamamoto, Shigeru Honda, Akika Kyo, Norihiko Misawa, and Takeya Kohno.
2024. "Switching to Intravitreal Brolucizumab after Ranibizumab or Aflibercept Using Treat and Extend Regimen for Neovascular Age-Related Macular Degeneration in Japanese Patients: 1-Year Results and Factors Associated with Treatment Responsiveness" Journal of Clinical Medicine 13, no. 15: 4375.
https://doi.org/10.3390/jcm13154375
APA Style
Hirayama, K., Yamamoto, M., Honda, S., Kyo, A., Misawa, N., & Kohno, T.
(2024). Switching to Intravitreal Brolucizumab after Ranibizumab or Aflibercept Using Treat and Extend Regimen for Neovascular Age-Related Macular Degeneration in Japanese Patients: 1-Year Results and Factors Associated with Treatment Responsiveness. Journal of Clinical Medicine, 13(15), 4375.
https://doi.org/10.3390/jcm13154375
